Why Iveric Bio Is Skyrocketing 24% Today

After reporting 18-month results from a phase 3 trial evaluating the drug Zimura in geographic atrophy on June 15, Iveric Bio (NASDAQ:ISEE) is tapping investors for more cash, increasing the likelihood its cash stockpile can last it through Zimura's clinical-stage development.